
Co-Founder/COO of 3D body tracker @shapescale. 💪 Data & fitness tech geek, dad and husband. 🏃👊🔥
San Francisco Bay Area
Joined February 2009
- Tweets1.4K
- Following745
- Followers927
- Likes24.2K
Martin Kessler retweeted
A hundred years ago, if your kid got diabetes, the doctor's plan was to starve them. 400 calories a day. Some weeks, nothing at all.
It sounds insane but there was a grim logic behind it. Type 1 diabetes killed children within months back then, and less food meant less sugar in the blood, which slowed the dying. Kids on the diet stopped dying of diabetes and died of starvation instead, just slower. Parents signed up anyway because one extra year with their child was the best medicine could offer.
Elizabeth Hughes was the daughter of the US Secretary of State, so she got the best care money could buy. That care took her from 75 pounds at diagnosis down to 45 pounds by age 14. When her mother brought her to Toronto in August 1922, she could barely walk.
The treatment waiting there almost never got made. Frederick Banting was a small-town surgeon whose practice was failing so badly he was nearly broke. He talked a university into lending him a lab for one summer, and with a 21-year-old student assisting, isolated the pancreatic hormone researchers had chased for 30 years.
Five weeks after her first shot, Elizabeth was eating 2,500 calories a day with a pint of cream poured on top. She gained 60 pounds in four and a half months. She went to Barnard, raised a family, lived to 73, and kept the diabetes secret from almost everyone she knew.
Banting refused to put his name on the patent. He'd sworn the Hippocratic oath and believed a doctor had no business profiting from something like this. His co-discoverers sold it to the University of Toronto for a dollar. "Insulin does not belong to me, it belongs to the world."
24 months from first injection to the Nobel Prize, and every diabetic kid on earth went from a death sentence to a normal life for the price of one dollar.
Martin Kessler retweeted
Exercise, the low cost way to "reverse aging"
science.org/doi/10.1126/scit…
Martin Kessler retweeted
The Wegovy pill may be doing something more important than taking market share from injectable GLP-1s: expanding the obesity treatment market.
A new study published in Annals of Internal Medicine examined the early uptake of oral semaglutide following its January 2026 launch.
The numbers are pretty remarkable:
🔹100,000 new monthly prescriptions by month 2**, compared with month 4 for Zepbound and month 20 for injectable Wegovy.
🔹4.4x faster early adoption** than Zepbound and 7.4x faster than injectable Wegovy, based on launch-aligned prescription growth.
🔹Injectable Wegovy prescriptions did NOT decline following the pill's introduction.
🔹Total Wegovy prescriptions (oral + injectable) increased substantially, although Zepbound continued to lead in overall prescription volume.
Here's what I find most interesting:
The introduction of an oral GLP-1 appears to be expanding the market rather than simply cannibalizing injectable therapies. This makes intuitive sense. Some patients don't want injections. Others may find a pill more approachable, even with the inconvenience of daily fasting administration. Of course, these are aggregate prescription data, so we can't definitively establish how many new patients entered treatment versus switched therapies.
But the broader implication is exciting.
We may have substantially underestimated the number of people willing to pursue pharmacotherapy for obesity once we offer them more choices.
And with additional oral obesity medications in development, this market could look very different in a few years.
Source: acpjournals.org/doi/10.7326/…
Martin Kessler retweeted
An AI health assistant in China reportedly surpassed 100 million users, offering services including free medical-report interpretation. While not a replacement for doctors, it shows how quickly access to health information can scale. The opportunity is enormous.
Martin Kessler retweeted

unusual_whales@unusual_whalesOct 10
North America
North AmericaConnected via North America App StoreAccount-level information, not a live location or per-post device.
11% of U.S. adults now take a GLP-1 for weight loss, roughly 28 million people, up from just 3% in 2024, per Gallup.
Martin Kessler retweeted
I was at an AI dinner last night in NYC.
Some interesting topics discussed
1. Performance engineers now spend most of their time managing agents and RSI loops. Most perf opts at major inference providers (together, fireworks) are found by agents.
2. RLing too much on code and math has negative effects on your model especially it’s language.
3. People were impressed by @bot and the overall acquisition of @cursor_ai by @spacexai. xAI is a legitimate frontier lab right now.
4. Most people have agents in loop writing, reviewing, and submitting PRs 24/7
5. Most agreed code review is not super productive anymore
6. Consensus was Fable 5.5 will be stunning but OpenAI will beat it in December with Bel
Martin Kessler retweeted
GLP-1 prescriptions to healthy US adults went up 15x from in 4 years (2021-2025).
None of them had type 2 diabetes or qualifying obesity.
This tells me that the market for healthy people who want to become healthier is as big as the market for sick people.
It's probably bigger.
Healthy people want more energy, sharper focus and, ultimately, more good years.
That's how GLP-1s went from a diabetes drug to a weight loss drug, and now to a lifestyle drug. I personally take retatrutide for focus as well, so I don't have to think about food.
The same thing happened to tadalafil. It was an ED pill, and now people take it for longevity.
I believe this is one of the signs that we are moving from sick care to performance medicine.
Martin Kessler retweeted
Amazon banning agents is the first opportunity I've seen since Amazon was founded for a startup to create an Amazon competitor. People will want agents to buy stuff for them. It will be one of the main use cases. And they won't want to use some Amazon-supplied agent to do it.
Martin Kessler retweeted
Mobile advertisers watching the open-web ad industry realize that Apple exerts absolute authority over its platform:
Martin Kessler retweeted
About vibe hardware - @danitpeleg3d is going viral with this on insta right now
I have watched her build an entire new business with codex from 0 to a new type of manufacturing
She literally prints bio based materials that people customize on her webapp
This is the future of manufacturing - and now also the future of fashion
I can’t believe she did all of this without 3d modelers (who she uses to spend a fortune on) or web developers etc
This fabric is never seen before.
Using ELEGOO OrangeStorm Giga, designer Danit Peleg @danitpeleg3d is turning her digital fashion concepts into physical reality.
On demand, no waste, no inventory, made to measure — this workflow can turn any creative idea into real items.
Martin Kessler retweeted
I am increasingly concerned about the AI psychosis inside Anthropic.
Imagine zealously trying to build something you believe to be a conscious god while running around claiming it will end the world.
NEW: According to a bombshell report in the New York Times, Anthropic co-founder Chris Olah threatened to walk out of Pope Leo XIV’s AI encyclical launch in May because the pope rejected the idea that machines can be conscious.
Olah’s team then privately lobbied the pope’s advisers “to take the possibility of model consciousness seriously.” Pope Leo XIV held firm.
For months, Anthropic has wined and dined theologians and religious scholars under nondisclosure agreements, hoping they would bless the idea that Claude has moral standing. thelettersfromleo.com/p/nyt-…
Martin Kessler retweeted
Replying to @hubermanlab @X
today's pointer was to this, for some data... and it gets better every month: xitter.cf/FutureJurvetson/status…
Martin Kessler retweeted
We are now entering into an era where any product can be created exactly to a consumer's preferences & needs.
I vibe-fabricated a dog door with a wifi-controlled lock, perfectly to the specifications & design of my house.
I know nothing about metal fabrication or electrical engineering.
It's now getting manufactured and delivered in 2 weeks -- for almost the same cost if I bought a mass-produced item off-the-shelf.
Martin Kessler retweeted
Your dad is about to give away your entire inheritance.
The whole point of building Tavus has been simple: talking to a machine should feel as natural as talking to a friend or coworker.
It’s hard to describe all the tiny nuances that make a conversation feel human. The little expressions. Moving around in your chair. Knowing when to speak and when to listen. The dance of it all.
Griffin is by far the closest anyone has come to a model that can capture those nuances. The first time I saw it being used, I had no idea I was watching our model rather than just a normal video call.
I’m so incredibly proud of this team and what they’ve built.
Martin Kessler retweeted
for those that don't grasp how crazy this is
GPT Image 2.5 Sunburst vs Ideogram 4.5
and by the way it's likely just simple masking/in-painting but it still surprises me it's not the default for the majority of image editing models.
you can tell it's in-painting because you can see the bush around my shoulder slowly turn into a line. it's the same reason my tattoos fade on why side of my arm (the closest to my t-shirt).
no excuse for chopping of half of my head though.
I'm going to have to try a workflow where I use this on every frame of a video.
Martin Kessler retweeted
🚨 Lilly may have just topped retatrutide.
Eloralintide 9 mg + tirzepatide 15 mg: 29% average weight loss at 31 weeks.
For context, retatrutide 12 mg produced 28.3% at 80 weeks in Phase 3 TRIUMPH-1.
Huge caveat: this was a tiny Phase 1b study, not a head-to-head trial.
But 29% in 31 weeks is a WILD efficacy signal.
$LLY $NVO
Martin Kessler retweeted
Bone health deserves attention before menopause, not just after.
Roughly two-thirds of bone lost across the menopausal transition tends to occur within a three-year window - from one year before to two years after the final menstrual period.
In a study of 862 women, bone density at the spine fell 10.6% over 10 years, but 7.4% was lost during this brief “transmenopause” period. Bone density of the femur fell 9.1%, with 5.8% lost during the same window.
This is a reason for women to prioritize resistance and high-impact training around the menopause transition to prevent or slow the loss of bone density.







































